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Abstract Elevated plasma free fatty acid (FFA), inXam-
matory marker, and altered adipokine concentrations have
been observed in obese type 2 diabetes patients. It remains
unclear whether these altered plasma concentrations are
related to the diabetic state or presence of obesity. In this
cross-sectional observational study, we compare basal
plasma FFA, inXammatory marker, and adipokine concen-
trations between obese and non-obese type 2 diabetes
patients and healthy, non-obese controls. A total of 20
healthy, normoglycemic males (BMI <30 kg/m2), 20 non-
obese (BMI <30 kg/m2) and 20 obese (BMI >35 kg/m2)
type 2 diabetes patients were selected to participate in this
study. Groups were matched for age and habitual physical
activity level. Body composition, glycemic control, and
exercise performance capacity were assessed. Basal blood
samples were collected to determine plasma leptin, adipo-
nectin, resistin, tumor necrosis factor  (TNF), inter-
leukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP)
and FFA concentrations. Plasma FFA, inXammatory
marker (hsCRP, IL-6, TNF), adipokine (adiponectin, resi-
stin, leptin), and triglyceride concentrations did not diVer
between non-obese diabetes patients and healthy, normo-
glycemic controls. Plasma FFA, IL-6, hsCRP, leptin, and
triglyceride levels were signiWcantly higher in the obese
diabetes patients when compared with the healthy normo-
glycemic controls (P < 0.05). Furthermore, plasma hsCRP
and leptin levels were signiWcantly higher in the obese ver-
sus non-obese diabetes patients (P < 0.05). SigniWcant cor-
relations between plasma parameters and glycemic control
were observed, but disappeared after adjusting for trunk
adipose tissue mass. Elevated plasma leptin, hsCRP, IL-6,
and FFA concentrations are associated with obesity and not
necessarily with the type 2 diabetic state.
Keywords Obesity · Diabetes · Adipokines · 
InXammation · Fat mass
Introduction
Obesity, and especially visceral adipose tissue accumula-
tion, increases the risk of developing type 2 diabetes
(Jensen 2008). The greater risk of type 2 diabetes in the
obese can, at least partly, be explained by changes in adi-
pose tissue function (Bastard et al. 2006; Hajer et al. 2008;
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Rasouli and Kern 2008). The classical perception of adipo-
cytes merely as a storage site for excess lipid has changed
dramatically over the last decade. This is attributed to the
discovery that adipose tissue can function as an active
endocrine organ, co-regulating whole-body metabolism.
An increase in adipose tissue mass is generally accompa-
nied by an increase in adipocyte size and macrophage inWl-
tration (Otto and Lande 2005). Greater adipose tissue mass,
adipocyte hypertrophy, and/or macrophage inWltration
strongly modulate adipose tissue lipolysis and the secretion
of numerous cytokines and adipokines (Hajer et al. 2008;
Wellen and Hotamisligil 2003). In accordance, elevated
plasma free fatty acid (FFA), leptin, resistin, tumor necrosis
factor   (TNF) and interleukin-6 (IL-6) concentrations
have been reported in the obese (Bastard et al. 2006; Hajer
et al. 2008; Rasouli and Kern 2008). In contrast, circulating
plasma adiponectin concentrations have been reported to be
reduced in the obese state. Furthermore, an increase in cir-
culating IL-6 concentration stimulates C-reactive protein
(CRP) synthesis in the liver (Bastard et al. 2006). Eventu-
ally, altered plasma adipokine, inXammatory factor, and/or
FFA levels can contribute to the development and/or pro-
gression of liver and skeletal muscle insulin resistance, and
induce pancreatic -cell apoptosis (Hajer et al. 2008).
The proposed impact of altered endocrine function of
adipose tissue on the development and/or progression of
type 2 diabetes has generally been studied in vivo in human
cross-sectional studies. In these studies, the above-men-
tioned plasma parameters have been assessed and com-
pared between type 2 diabetes patients and normoglycemic
controls (Al-Daghri et al. 2003; Al-Harithy and Al-Ghamdi
2005; Bastard et al. 2002; Bullo et al. 2002; Carey et al.
2004; HaVner et al. 1996; Heilbronn et al. 2004; Kim et al.
2006; Liu et al. 1999; Miyazaki et al. 2003; Putz et al. 2004;
Rieusset et al. 2004; Sivitz et al. 2003; Tatti et al. 2001;
Merwe van der et al. 2001; Yu et al. 2002). In general, most
of the type 2 diabetes patients included in these studies
were obese. Therefore, it remains unclear whether the
observed alterations in plasma FFA’s, adipokines, and/or
inXammatory parameters in type 2 diabetes patients are due
to excess adipose tissue mass and/or directly associated
with the type 2 diabetic state. To diVerentiate between the
impact of obesity and type 2 diabetes on the altered plasma
FFA, adipokine, and/or inXammatory proWles several
groups have compared plasma proWles between lean and
obese type 2 diabetes patients (Abdelgadir et al. 2005;
Bahceci et al. 2007; Chanchay et al. 2006; Hasegawa et al.
2005; Hotta et al. 2000; Marita et al. 2005; Sayeed et al.
2003; Yang et al. 2006). Elevated plasma FFA and IL-6,
but unaltered TNF, levels have been reported in non-obese
T2DM patients, when compared with body mass index
matched normoglycemic controls (Bahceci et al. 2007;
Yang et al. 2006). Whether plasma C-reactive protein,
adiponectin, leptin, and/or resistin concentrations are
altered in non-obese type 2 diabetes patients when com-
pared with healthy controls, remains unclear (Abdelgadir
et al.  2005; Bahceci et al. 2007; Chanchay et al. 2006;
Hasegawa et al. 2005; Hotta et al. 2000; Marita et al. 2005;
Sayeed et al. 2003; Yang et al. 2006). So far, these data
have only been obtained in Asian and Mid-Eastern popula-
tions. Due to apparent diVerences in adipose tissue distribu-
tion (Banerji et al. 1999) and the level of insulin resistance
(Chandalia et al. 1999) between ethnic groups, these Wnd-
ings do not necessarily apply to a Caucasian population.
Moreover, in none of these studies habitual physical activ-
ity was controlled between groups. DiVerent levels of habit-
ual physical activity might aVect plasma adipokine and
inXammatory marker levels (You and Nicklas 2008).
Clearly, proper control of habitual activity is warranted
when comparing such plasma parameters between groups.
We hypothesize that altered plasma adipokine, inXam-
matory factor, and/or FFA levels are related to the obese
state only and are not prevalent in non-obese type 2 diabe-
tes patients. The present study compares basal plasma
FFA’s, adipokines, and inXammatory markers between
obese and non-obese type 2 diabetes patients versus non-
obese, normoglycemic controls. This comparison increases
our insight in the proposed impact of obesity in the devel-
opment and/or progression of type 2 diabetes.
Methods
Subjects
A total of 60 Caucasian males were selected to participate
in this study: 20 non-obese (BMI <30 kg/m2) and 20 obese
(BMI >35 kg/m2) type 2 diabetes patients, and 20 healthy,
non-obese subjects (BMI <30 kg/m2; see Table 1). Type 2
diabetes patients had been diagnosed for at least 12 months
prior to investigation and were all treated with oral blood
glucose lowering medication. All subjects were sedentary
and had not participated in any regular exercise and/or calo-
ric intake restriction program for at least 5 years. Subjects
were informed about the nature and risks of the experimen-
tal procedures before their written informed consent was
obtained. This study was approved by the local medical
ethical committee of the Jessa Hospital.
Study design
Overall, groups were matched for age and habitual physical
activity. The latter was estimated by the use of the IPAQ
questionnaire. Additionally, non-obese type 2 diabetes
patients and normoglycemic controls were matched for
body mass index. Non-obese and obese type 2 diabetesEur J Appl Physiol (2010) 109:397–404 399
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patients were matched for basal fasting glucose concentra-
tions. Fasting blood samples were collected to compare
glycosylated hemoglobin (HbA1c) content, blood lipid pro-
Wle, insulin, adiponectin, resistin, leptin, interleukin-6,
high-sensitivity C-reactive protein, TNF, and FFA con-
centrations between groups. Moreover, HOMA index, fat
free mass and whole-body oxygen uptake and workload
capacity were compared between groups. All measure-
ments were performed at the same time during the day
(between 8.00 and 12.00 AM).
Medication, diet and physical activity prior to testing
Three days prior to testing subjects abstained from taking
oral blood glucose and/or lipid lowering medication. All
subjects maintained normal physical activity and dietary
patterns, and refrained from any sort of heavy physical
exercise/labor for at least 3 days prior to testing. The even-
ing prior to the test day, all subjects received the same
standardized meal (45 § 1k Jk g ¡1, consisting of 33
energy% (En%) carbohydrate, 47 En% fat, and 20 En%
protein). Daily habitual physical activity over the last
2 weeks was estimated by the International Physical Activ-
ity Questionnaire (IPAQ) (Craig et al. 2003).
Blood analysis
Subjects arrived at the hospital by car or public transporta-
tion and reported at the laboratory at 08.00 AM after an
overnight fast. After 20 min of rest a venous blood sample
was collected. Thereafter, a 2 h oral glucose tolerance test
(OGTT) was performed. Plasma samples were immediately
centrifuged at 1,000 g and 4°C for 5 min, after which ali-
quots of plasma were frozen in liquid nitrogen and stored at
¡80°C until analysis. Blood samples were analyzed for
glucose (Beckman Synchron LX 20 Analyser, Beckman
Coulter Inc., USA), insulin (Advia Centaur Immunoassay
System, Bayer Diagnostics Inc., USA), total cholesterol,
Table 1 Subjects’ 
characteristics
Healthy 
controls
Non-obese 
diabetes
Obese 
diabetes
Number 20 20 20
Age (years) 55 § 15 8 § 15 6 § 1
Body mass index (kg/m2) 26.1 § 0.4 26.6 § 0.4 35.6 § 0.6*‡
Body weight (kg) 79.9 § 1.7 81.2 § 1.5 108.4 § 2.8*‡
Glycemic control
Fasting glucose (mmol/L) 5.8 § 0.2 9.7 § 0.6‡ 10.9 § 0.8‡
AUC OGTT (mol min/L) 0.92 § 0.04 1.76 § 0.09‡ 1.86 § 0.09‡
Disease duration (years) 0 § 06 . 2 § 1.2‡ 4.5 § 0.9‡
Insulin (mU/L) 10.3 § 0.9 12.1 § 1.2 21.6 § 2.6*‡
HOMA index 2.6 § 0.2 5.2 § 0.7‡ 9.6 § 0.9*‡
HbA1c (%) 5.4 § 0.1 7.0 § 0.2‡ 8.0 § 0.4*‡
Blood lipid proWle
Total cholesterol (mmol/L) 5.6 § 0.2 5.0 § 0.2 5.3 § 0.2
HDL cholesterol (mmol/L) 1.4 § 0.1 1.2 § 0.1 1.1 § 0.1‡
LDL cholesterol (mmol/L) 3.7 § 0.2 3.3 § 0.2 3.6 § 0.1
Triglycerides (mmol/L) 1.4 § 0.1 1.2 § 0.2 2.2 § 0.2*‡
Body composition
Adipose tissue mass legs (kg) 5.2 § 0.4 4.6 § 0.3 9.2 § 0.6*‡
Adipose tissue mass trunk (kg) 13.2 § 0.7 14.4 § 0.6 26.2 § 1.2*‡
Adipose tissue mass total body (kg) 20.9 § 1.1 21.8 § 0.9 -
Fat free mass legs (kg) 18.3 § 0.4 17.3 § 0.4 19.4 § 0.5
Fat free mass trunk (kg) 27.7 § 0.6 29.0 § 0.5 32.8 § 0.8*‡
Exercise performance capacity
VO2peak (L/min) 2.5 § 0.1 2.3 § 0.1 2.1 § 0.1
VO2peak (mL/kg leg fat free mass/min) 135 § 6 131 § 71 0 7 § 5*‡
Wmax 221 § 10 174 § 30‡ 155 § 37‡
Habitual physical activity (min/week) 118 § 33 72 § 24 80 § 33
Smokers (n) 2 2 3
Data represent means § SEM
Fasting glucose, insulin, HOMA 
index, and AUC OGTT were all 
determined from an OGTT per-
formed after 3 days of discontin-
uation of habitual use of oral 
blood glucose and lipid lowering 
medication
HOMA homeostasis model 
assessment, HbA1c glycosylated 
hemoglobin, AUC area under the 
curve, OGTT oral glucose toler-
ance test, HDL high-density 
lipoprotein, LDL low-density 
lipoprotein, VO2peak peak whole-
body oxygen uptake capacity, 
Wmax maximal workload capac-
ity
Leg fat free and adipose tissue 
mass are expressed as average of 
the two legs
*S i g n i Wcantly diVerent between 
non-obese and obese T2DM 
patients (P <0 . 0 5 )
‡ SigniWcantly diVerent com-
pared with healthy controls 
(P <0 . 0 5 )400 Eur J Appl Physiol (2010) 109:397–404
123
high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, and total plasma triglycerides
(Beckman Synchron LX 20 Analyser, Beckman Coulter
Inc., USA). HOMA index was calculated to estimate whole-
body insulin sensitivity: [(insulin(mU/L) £ glucose(mmol/L)]/
22.5. Plasma adiponectin concentrations were assessed
using a commercially available Human Adiponectin ELISA
assay kit (HADP-61K, Linco Research Inc., St. Charles,
MO, USA). TNF concentrations were determined using a
solid-phase, chemiluminescent immunometric assay
(IMMULITE TNF-, DPC Biermann GmbH, Bad Nauheim,
Germany). Plasma high-sensitivity C-reactive protein
(hsCRP) concentrations were measured by means of immu-
noephelometry (Cardiophase, Dade Behring GmbH, Mar-
burg, Germany). Resistin concentrations were assessed by
enzyme-substrate reaction with a commercially available
assay kit (ELISA, Phoenix Pharmaceuticals, USA). Plasma
free fatty acid (FFA) levels were quantiWed by enzymatic
method using a commercially available assay kit from Wako
Chemicals GmbH, Germany. Plasma interleukin-6 (IL-6)
levels were assessed by a solid-phase, enzym-labeled, chemi-
luminiscent sequential immunometric assay (IMMULITE
1000 analyzer, EURO/DPC Ltd, UK). In addition, a small
blood sample was used to determine blood HbA1c content
(Hi-Auto A1c Analyser, Menarini Diagnostics Inc., Italy).
Whole-body oxygen uptake capacity
Peak whole-body oxygen uptake capacity (VO2peak) and
workload capacity (Wmax) was assessed during an exhaus-
tive incremental exercise test on a calibrated cycle ergome-
ter (Ergo 1500 cycle, ErgoWt GmbH, Pirmasens, Germany)
using a 3-min work stage protocol (Fletcher et al. 2001).
Oxygen uptake (VO2) measurements were performed con-
tinuously (CS 200, Schiller AG, Switzerland). The heart
was monitored using a 12-lead electrocardiogram with
heart rate being recorded continuously.
Body composition
Body mass was measured using a calibrated analogue
weight scale (Tanita model TBF-300, Tanita Corp.,
Tokyo, Japan). Segmental and whole-body adipose tissue
mass and fat free mass were determined using whole-body
dual X-ray absorptiometry (Lunar DPXL, Wisconsin,
USA) (Glickman et al. 2004). In healthy subjects and non-
obese type 2 diabetes patients, whole-body as well as seg-
mental (legs and trunk) adipose tissue and fat free mass
were assessed. However, in the obese diabetes patients,
only segmental (legs and trunk) adipose tissue and fat free
mass were assessed, as the arms did not Wt properly under
the scanner.
Statistical analysis
Data are expressed as means § SEM. To compare three
groups simultaneously, multiple one-way analysis of vari-
ance (MANOVA), with Tukey’s post hoc test, were
applied. In addition, relations between parameters were
analyzed by Pearson correlation coeYcients or by multiple
regression analysis. Statistical signiWcance was set at
P < 0.05. All calculations were performed using the Statis-
tical Package for the Social Sciences v. 15.0 (SPSS).
Results
Subjects
A total of 20 Caucasian, non-obese and obese type 2 diabe-
tes patients, and 20 non-obese normoglycemic controls
were included in this study (Table 1). The diabetes patients
were all using oral blood glucose lowering medication (sul-
famides 25%, biguanides 70%, -glucosidase inhibitors
2%, thiazolidinediones 7%, and glinides 10%) and had
been diagnosed with type 2 diabetes for 5.4 § 0.7 years.
Non-obese type 2 diabetes patients and normoglycemic
controls were matched for body mass index. Trunk and
whole-body adipose tissue mass were similar between
groups (P > 0.05). In addition, non-obese and obese type 2
diabetes patients were matched for fasting blood glucose. In
accordance, oral glucose tolerance and time since diagnosis
did not diVer between groups (P > 0.05). Habitual physical
activity patterns did not diVer between normoglycemic con-
trols, non-obese and obese type 2 diabetes patients
(P >0 . 0 5 ) .
Glycemic control
Glycemic control was signiWcantly impaired in non-obese
and obese diabetes patients when compared with healthy,
normoglycemic controls (as indicated by AUC during
OGTT; P < 0.05). In addition, blood HbA1c content, fasting
insulin, and HOMA index were signiWcantly elevated in the
obese compared with non-obese type 2 diabetes patients
(Table 1; P <0 . 0 5 ) .
Blood lipid proWle
Plasma HDL cholesterol levels were signiWcantly lower
in obese diabetes patients when compared with normo-
glycemic controls (P < 0.05). Plasma triglyceride levels
were signiWcantly higher in the obese when compared
with non-obese patients and normoglycemic controls
(P <0 . 0 5 ) .Eur J Appl Physiol (2010) 109:397–404 401
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Exercise performance capacity
Whole-body oxygen uptake capacity (VO2peak) did not
diVer signiWcantly between groups (Table 1). When
expressed per kg leg fat free mass, VO2peak was signiW-
cantly lower in the obese when compared with non-obese
type 2 diabetes patients and normoglycemic controls
(P < 0.05). Maximal workload capacity (Wmax) was signiW-
cantly greater in normoglycemic controls when compared
with obese and non-obese diabetes patients (P <0 . 0 5 ) .
Plasma adipokines and free fatty acids
Basal plasma adipokine (adiponectin, leptin, resistin), FFA,
and inXammatory marker (hsCRP, IL-6) concentrations are
presented in Fig. 1. No signiWcant diVerences were
observed between non-obese diabetes patients and normo-
glycemic controls (P > 0.05). Plasma FFA, IL-6, hsCRP,
and leptin levels were signiWcantly higher in obese diabetes
patients when compared with normoglycemic controls
(P < 0.05). Furthermore, plasma hsCRP and leptin levels
Fig. 1 Plasma FFA, inXamma-
tory marker and adipokine con-
centrations. Data are expressed 
as means § SEM. *SigniWcantly 
diVerent between obese T2DM 
patients and other subgroups 
(P < 0.05). No signiWcant diVer-
ences were found between 
healthy subjects and non-obese 
T2DM patients (P > 0.05). Plas-
ma leptin (a), adiponectin (b), 
resistin (c), free fatty acid (d), 
interleukin-6 (e), high-sensitiv-
ity C-reactive protein (f), and 
tumor necrosis factor  (g) 
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were signiWcantly elevated in obese versus non-obese dia-
betes patients (P <0 . 0 5 ) .
Correlations and multivariate regression analysis
Univariate correlations between plasma factors, adipose tis-
sue mass, VO2peak, and glycemic control are displayed in
Table 2. In total subject population, plasma FFA, leptin,
hsCRP, and IL-6 concentrations correlated signiWcantly
with measures of glycemic control (P < 0.05). These corre-
lations were no longer evident when plasma concentrations
were adjusted for trunk adipose tissue mass in multivariate
regression analysis (P >0 . 0 5 ) .
Discussion
The present study compares basal plasma adipokine,
inXammatory marker, and FFA concentrations between
non-obese and obese type 2 diabetes patients versus non-
obese normoglycemic controls. We show that basal plasma
FFA, high-sensitivity C-reactive protein (hsCRP), interleu-
kin-6 (IL-6), leptin, and triglyceride levels are elevated in
obese type 2 diabetes patients, as opposed to healthy, nor-
moglycemic controls (Fig. 1; Table 1). On the other hand,
no such diVerences were found between non-obese type 2
diabetes patients and healthy normoglycemic controls.
Consequently, altered plasma FFA, IL-6, hsCRP, and leptin
levels seem to be more related to adipose tissue mass than
to the presence or absence of the type 2 diabetic state and/or
the level of glycemic control. This is further supported by
the observation that parameters that assess glycemic control
were no longer correlated with plasma FFA, IL-6, hsCRP and
leptin levels when data were adjusted for trunk adipose tissue
mass (Table 2). Therefore, our Wndings suggest that elevated
basal plasma FFA, IL-6, hsCRP, and leptin concentrations
are not necessarily related to the type 2 diabetic state.
Our Wndings seem to be in contrast with Wndings from
some, but not all, studies which show that in non-obese
type 2 diabetes patients, plasma FFA, IL-6, and CRP con-
centrations are higher, and adiponectin and leptin levels
are lower, when compared with matched normoglycemic
controls (Abdelgadir et al. 2005; Bahceci et al. 2007;
Chanchay et al. 2006; Hasegawa et al. 2005; Hotta et al.
2000; Marita et al. 2005; Sayeed et al. 2003; Yang et al.
2006). This might be attributed to diVerences in the ethnic
background of the volunteers in the diVerent studies
(Carroll et al. 2009; Lee and Jensen 2009; Reimann et al.
2007), which show large diVerences in adipose tissue mass
distribution and/or the level of insulin resistance (Banerji
et al. 1999; Chandalia et al. 1999). For example, Asian and
Mid-Eastern populations show a relatively greater truncal
adipose tissue mass when compared with BMI-matched
Caucasians (Banerji et al. 1999; Chandalia et al. 1999).
This might be accompanied by diVerences in adipokine and
inXammatory marker secretion between populations of
various ethnic backgrounds. Additionally, in none of these
studies habitual physical activity was controlled for
between groups. DiVerent levels of habitual activity are
likely to aVect plasma adipokine and inXammatory marker
levels, complicating the interpretation of such Wndings
(You and Nicklas 2008).
Recent in vitro studies examined the relation between
adipocyte size and adipokine/inXammatory factor release/
Table 2 Univariate correlations 
of blood parameters, adipose 
tissue mass, and VO2peak 
with glycemic control
Glycemic control
AUC 
OGTT
Fasting glucose 
(mmol/L)
HbA1c 
(%)
HOMA 
index
Blood parameters
Free fatty acids (mol/L) 0.50 0.48 0.53 0.46
Adiponectin (ng/mL)
Leptin (ng/mL) 0.46 0.51 0.62 0.72
Resistin (ng/mL)
High-sensitivity C-reactive protein (mg/L) 0.45 0.44 0.39 0.56
Interleukin-6 (pg/mL) 0.50 0.47 0.44 0.37
Tumor necrosis factor  (pg/mL)
Body composition
Trunk adipose tissue mass (kg) 0.51 0.54 0.63 0.69
Leg adipose tissue mass (kg) 0.38 0.44 0.50 0.56
Exercise performance capacity
VO2peak (L/min) ¡0.29 ¡0.33 ¡0.26 ¡0.31
VO2peak (mL/min/kg leg fat free mass) ¡0.29 ¡0.36 ¡0.31 ¡0.48
Values provided in this table 
represent R values; only signiW-
cant correlations are mentioned 
in this table (P <0 . 0 5 )
AUC area under the curve, 
OGTT oral glucose tolerance 
test, HOMA homeostasis model 
assessment, VO2peak peak whole-
body oxygen uptake capacity, 
HbA1c glycosylated hemoglobinEur J Appl Physiol (2010) 109:397–404 403
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expression derived from Caucasian human subcutaneous
adipose tissue biopsies (Jernas et al. 2006; Skurk et al.
2007). These studies indicate that leptin and IL-6 secretion
were signiWcantly greater in enlarged adipocytes. No such
relation was observed for adipocyte size and TNF and/or
adiponectin release. Moreover, a correlation between serum
amyloid A (SAA) gene expression in human adipocytes
and adipocyte size has previously been reported (Jernas
et al.  2006). SAA is an acute-phase protein involved in
inXammation, and contributes to adipocyte-derived CRP
and IL-6 release. A correlation between adipocyte-derived
FFA release and adipocyte size has been well-established.
These  Wndings seem to agree with our observation that
plasma hsCRP, FFA, leptin and IL-6 are no longer signiW-
cantly correlated with the level of glycemic control when
adjusted for trunk adipose tissue mass. Consequently, we
conclude that alterations in plasma FFA, IL-6, hsCRP, and
leptin levels in obese type 2 diabetes patients are attributed
to the greater adipose tissue mass, and not necessarily to the
presence of the type 2 diabetic state.
Data from the present study imply that systemic low-
grade inXammation, a disturbed blood lipid proWle, and
lowered oxygen uptake capacity are more prevalent in
obese, as opposed to non-obese, type 2 diabetes patients.
The development of type 2 diabetes in subjects with excess
adipose tissue mass is currently believed to be related to
many factors. Besides genetic predisposition and ethnicity,
a low skeletal muscle oxidative capacity and/or altered pro-
tein/cytokine secretion from adipocytes is linked to impair-
ments in whole-body carbohydrate metabolism. However,
we failed to observe any signiWcant diVerences in whole-
body oxygen uptake capacity and/or blood plasma adipo-
kine and inXammatory markers levels in the non-obese type
2 diabetes patients when compared to the matched normo-
glycemic controls. Therefore, other factors are likely to
play a more prominent role in the etiology of insulin resis-
tance and type 2 diabetes in the non-obese population.
One of the more challenging features of this work was
the inclusion of non-obese type 2 diabetes patients. Recent
studies report that only »10% of all Caucasian type 2 dia-
betes patients have a normal lean phenotype, whereas more
than 60% is obese (Kramer et al. 2009). Nonetheless, the
comparison of plasma adipokine and inXammatory marker
concentrations in non-obese and obese type 2 diabetes
patients generates the possibility to diVerentiate between
the impact of type 2 diabetes and obesity.
This study has some important clinical implications. The
presented data conWrm that obese type 2 diabetes patients
are clearly at a high risk of developing cardiovascular dis-
ease (based on body composition, blood lipid proWle and
inXammation parameters, oxygen uptake capacity). Based
on these parameters, the non-obese type 2 diabetes patients
seem to be at a lower risk of developing cardiovascular
complications. Since strong correlations have been reported
between low-grade inXammation, disturbed blood lipid pro-
Wle, reduced whole-body oxidative capacity, and the risk of
developing cardiovascular complications, obese type 2 dia-
betes patients should be stimulated to adhere to eVective
exercise, nutritional, and pharmaceutical intervention to
reduce excess adipose tissue mass and improve glycemic
control. Interestingly, our data show that the proposed link
between plasma adipokines, inXammation parameters, FFA
and type 2 diabetes are more related to the level of adipos-
ity, as opposed to insulin sensitivity and/or glycemic con-
trol. Further study remains warranted to elucidate the
proposed role of these plasma parameters in the etiology of
obesity and/or type 2 diabetes.
In conclusion, elevated plasma FFA, IL-6, hsCRP, lep-
tin, and triglyceride concentrations are observed in obese,
as opposed to non-obese, type 2 diabetes patients. Elevated
plasma leptin, hsCRP, IL-6, and FFA concentrations are
attributed to the prevalence of obesity and not necessarily
associated with the type 2 diabetic state.
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